マイコプラズマ検査の市場規模、シェア、動向分析：製品別、技術別、用途別、最終用途別、地域別、セグメント別予測、2024年～2030年

マイコプラズマ検査市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のマイコプラズマ検査市場規模は2030年までに22億6,000万米ドルに達し、予測期間中に13.58%のCAGRを記録する見込みです。

市場拡大の主な要因としては、バイオ製造におけるマイコプラズマ検査需要の拡大、新興国、医薬アウトソーシングの拡大などが挙げられます。さらに、市場全体の成長は、細胞株汚染の増加、生物科学における技術革新と研究が牽引しています。

製薬企業やバイオテクノロジー企業を支援する政府のイニシアチブの増加も市場成長の原動力となっています。米国FDAは、体外生細胞培養内のマイコプラズマを検出するための検査を、単一の検査法のみを特定するのに役立つとして削除することを提案しました。このような生物製剤規制の変更により、マイコプラズマ検出検査の特異性と感度が向上し、業界における新技術のイントロダクションつながると予想されます。このことは、新製品開発において主要なプレーヤーに絶大な機会をもたらすと予想されます。

M.pneumoniae陽性率は、2019年末のCOVID-19パンデミックアウトブレイク中に急激に減少しました。これは、COVID-19パンデミックの厳しい規制がM.肺炎の蔓延を止めることに成功した結果です。しかし、COVID-19の規制緩和後、調査期間を通じてM.肺炎はさらに拡大すると予想され、マイコプラズマ検査市場の成長に好影響を与えると思われます。

研究開発への投資の増加は、市場の収益拡大に大きく寄与しています。ヘルスケア支出の増加に伴い、ライフサイエンス業界の研究活動は大幅に増加しています。創薬開発のための新技術の採用や細胞培養技術の革新が、マイコプラズマ検査の需要を押し上げています。細胞培養汚染の高いリスクは、予測期間にわたってマイコプラズマ検査市場を牽引すると予想される主な要因です。

マイコプラズマは、世界中の継続的な細胞培養の約15％～35％を汚染していると推定されています。190種以上のマイコプラズマが知られているが、8種のみが細胞培養汚染の95％以上を引き起こしています。不十分な培養方法、エアロゾル、ほこり、層流の不具合や破損による交差汚染が、細胞培養の汚染件数を増加させている要因の一部です。このような要因は、マイコプラズマ検査ソリューションの市場需要を促進すると考えられます。

マイコプラズマ検査市場レポートハイライト

• 製品別では、キットと試薬が市場を独占し、予測期間を通じて最も速いCAGRを示すと予測されます。
• PCR法が提供する主な利点は、手順の容易さと迅速な検出です。
• アプリケーション別では、細胞培養分野で行われる研究プロジェクトの増加により、細胞株検査セグメントが2023年に41.65%の最大シェアを占めました。
• マイコプラズマ汚染は、細胞培養代謝産物の変化を引き起こし、毒素の開発につながる可能性があります。このため、製薬・バイオ医薬品業界では細胞株検査と認証の重要性が高まっています。
• 北米は2023年に39.04％の最大シェアを占めました。これは、市場参入企業が多いことに加え、研究開発費の増加や連邦政府の援助が主な要因です。
• アジア太平洋では、高齢化に伴う対象疾患の有病率の上昇、認知度の向上などの要因によって、予測される期間中に最も高い成長率が見込まれます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

• 市場セグメンテーションと範囲
• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場動向と展望
• 市場力学
  • ライフサイエンスへの研究開発投資の増加
  • 製薬およびバイオテクノロジー産業に対する政府の支援の増加
  • 細胞培養汚染の増加
  • 生命を脅かす病気の効果的な治療法イントロダクション対する需要の高まり
  • 市場での競合の激化
• 市場抑制要因分析
  • 細胞生物学の調査費は高額
  • マイコプラズマの増殖速度が遅い
  • 偽陰性結果の可能性
• 事業環境分析
  • SWOT分析;要因別（政治・法律、経済・技術）
  • ポーターのファイブフォース分析
• COVID-19感染症の影響分析

第4章 製品ビジネス分析

• マイコプラズマ検査市場：製品の変動分析
• 機器
  • 機器市場、2018～2030年
• キットと試薬
  • キットおよび試薬市場、2018～2030年
  • PCRアッセイ
  • 核酸検出キット
  • 汚れ
  • 除去キット
  • 基準と管理
  • その他
• サービス
  • サービス市場、2018-2030（100万米ドル）

第5章 テクノロジービジネス分析

• マイコプラズマ検査市場：技術変動分析
• PCR
• エリサ
• 直接アッセイ
• 間接アッセイ
• 微生物培養技術
• 酵素による方法

第6章 アプリケーションビジネス分析

• マイコプラズマ検査市場：アプリケーションの変動分析
• 細胞株の検査
  • 細胞株検査市場、2018～2030年
• ウイルス検査
  • ウイルス検査市場、2018～2030年
• 生産終了セルのテスト
  • 生産終了セル検査市場、2018～2030年
• その他
  • その他市場、2018-2030

第7章 最終用途ビジネス分析

• マイコプラズマ検査市場：最終用途の変動分析
• 製薬およびバイオテクノロジー企業
• 細胞バンク
• 受託調査機関
• 学術調査機関
• その他

第8章 地域ビジネス分析

• 地域別マイコプラズマ検査市場シェア、2023年および2030年
• 北米
  • SWOT分析
  • 北米マイコプラズマ検査市場、2018年から2030年
  • 米国
  • カナダ
• 欧州
  • SWOT分析
  • 欧州のマイコプラズマ検査市場、2018年から2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
  • ロシア
• アジア太平洋地域
  • SWOT分析
  • アジア太平洋地域のマイコプラズマ検査市場、2018年から2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
  • シンガポール
• ラテンアメリカ
  • SWOT分析
  • ラテンアメリカのマイコプラズマ検査市場、2018年から2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • SWOT分析
  • MEAマイコプラズマ検査市場、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 企業の分類
• 戦略マッピング
  • 新製品の発売
  • パートナーシップ
  • 買収
  • コラボレーション
  • 資金調達
• 主要企業の市場シェア分析、2023年
• 企業プロファイル
  • Thermo Fisher Scientific, Inc.
  • Merck &Co., Inc.
  • Lonza Group AG
  • Charles River Laboratories International, Inc.
  • PromoCell GmbH
  • Asahi Kasei Medical Co., Ltd.
  • Sartorius AG
  • InvivoGen
  • Eurofins Scientific
  • （ATCC）American Type Culture Collection

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Mycoplasma Testing Market, by Region, 2018 - 2030 (USD Million)
• Table 4 Global Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 5 Global Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 6 Global Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 7 Global Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 8 North America Mycoplasma Testing Market, by Country, 2018 - 2030 (USD Million)
• Table 9 North America Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 10 North America Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 11 North America Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 12 North America Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 13 U.S. Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 14 U.S. Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 15 U.S. Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 16 U.S. Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 17 Canada Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 18 Canada Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 19 Canada Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 20 Canada Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 21 Europe Mycoplasma Testing Market, by Country, 2018 - 2030 (USD Million)
• Table 22 Europe Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 23 Europe Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 24 Europe Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 25 Europe Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 26 Germany Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 27 Germany Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 28 Germany Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 29 Germany Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 30 UK Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 31 UK Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 32 UK Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 33 UK Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 34 France Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 35 France Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 36 France Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 37 France Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 38 Italy Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 39 Italy Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 40 Italy Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 41 Italy Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 42 Spain Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 43 Spain Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 44 Spain Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 45 Spain Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 46 Denmark Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 47 Denmark Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 48 Denmark Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 49 Denmark Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 50 Sweden Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 51 Sweden Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 52 Sweden Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 53 Sweden Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 54 Norway Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 55 Norway Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 56 Norway Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 57 Norway Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 58 Russia Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 59 Russia Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 60 Russia Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 61 Russia Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific Mycoplasma Testing Market, by Country, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 66 Asia Pacific Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 67 China Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 68 China Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 69 China Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 70 China Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 71 Japan Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 72 Japan Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 73 Japan Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 74 Japan Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 75 India Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 76 India Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 77 India Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 78 India Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 79 South Korea Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 80 South Korea Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 81 South Korea Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 82 South Korea Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 83 Australia Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 84 Australia Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 85 Australia Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 86 Australia Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 87 Thailand Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 88 Thailand Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 89 Thailand Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 90 Thailand Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 91 Singapore Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 92 Singapore Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 93 Singapore Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 94 Singapore Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 95 Latin America Mycoplasma Testing Market, by Country, 2018 - 2030 (USD Million)
• Table 96 Latin America Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 97 Latin America Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 98 Latin America Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 99 Latin America Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 100 Brazil Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 101 Brazil Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 102 Brazil Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 103 Brazil Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 104 Mexico Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 105 Mexico Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 106 Mexico Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 107 Mexico Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 108 Argentina Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 109 Argentina Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 110 Argentina Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 111 Argentina Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 112 Middle East & Africa Mycoplasma Testing Market, by Country, 2018 - 2030 (USD Million)
• Table 113 Middle East & Africa Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 114 Middle East & Africa Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 115 Middle East & Africa Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 116 Middle East & Africa Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 117 South Africa Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 118 South Africa Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 119 South Africa Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 120 South Africa Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 121 Saudi Arabia Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 122 Saudi Arabia Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 123 Saudi Arabia Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 124 Saudi Arabia Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 125 UAE Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 126 UAE Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 127 UAE Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 128 UAE Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)
• Table 129 Kuwait Mycoplasma Testing Market, by Product, 2018 - 2030 (USD Million)
• Table 130 Kuwait Mycoplasma Testing Market, by Application, 2018 - 2030 (USD Million)
• Table 131 Kuwait Mycoplasma Testing Market, by Technology, 2018 - 2030 (USD Million)
• Table 132 Kuwait Mycoplasma Testing Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Mycoplasma Testing Market Segmentation
• Fig. 8 Market Snapshot, 2023
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 Global Mycoplasma Testing Market: by Product Movement Analysis
• Fig. 16 Global Mycoplasma Testing Market, for Instruments, 2018 - 2030 (USD Million)
• Fig. 17 Global Mycoplasma Testing Market, for Kits & Reagents, 2018 - 2030 (USD Million)
• Fig. 18 Global Mycoplasma Testing Market, for PCR Assays, 2018 - 2030 (USD Million)
• Fig. 19 Global Mycoplasma Testing Market, for Nucleic Acid Detection Kits, 2018 - 2030 (USD Million)
• Fig. 20 Global Mycoplasma Testing Market, for Stains, 2018 - 2030 (USD Million)
• Fig. 21 Global Mycoplasma Testing Market, for Elimination Kits, 2018 - 2030 (USD Million)
• Fig. 22 Global Mycoplasma Testing Market, for Standards & Controls, 2018 - 2030 (USD Million)
• Fig. 23 Global Mycoplasma Testing Market, for Others, 2018 - 2030 (USD Million)
• Fig. 24 Global Mycoplasma Testing Market, for Services, 2018 - 2030 (USD Million)
• Fig. 25 Global Mycoplasma Testing Market: Technology Movement Analysis
• Fig. 26 Global Mycoplasma Testing Market, for PCR, 2018 - 2030 (USD Million)
• Fig. 27 Global Mycoplasma Testing Market, for ELISA, 2018 - 2030 (USD Million)
• Fig. 28 Global Mycoplasma Testing Market, for Direct Assay, 2018 - 2030 (USD Million)
• Fig. 29 Global Mycoplasma Testing Market, for Indirect Assay, 2018 - 2030 (USD Million)
• Fig. 30 Global Mycoplasma Testing Market, for Microbial Culture Techniques, 2018 - 2030 (USD Million)
• Fig. 31 Global Mycoplasma Testing Market, for Enzymatic Methods, 2018 - 2030 (USD Million)
• Fig. 32 Global Mycoplasma Testing Market: Application Movement Analysis
• Fig. 33 Global Mycoplasma Testing Market, for Cell Line Testing, 2018 - 2030 (USD Million)
• Fig. 34 Global Mycoplasma Testing Market, for Virus Testing, 2018 - 2030 (USD Million)
• Fig. 35 Global Mycoplasma Testing Market, for End of Production Cells Testing, 2018 - 2030 (USD Million)
• Fig. 36 Global Mycoplasma Testing Market, for Other Applications, 2018 - 2030 (USD Million)
• Fig. 37 Global Mycoplasma Testing Market: End-use Movement Analysis
• Fig. 38 Global Mycoplasma Testing Market, for Pharmaceutical & Biotechnology Companies, 2018 - 2030 (USD Million)
• Fig. 39 Global Mycoplasma Testing Market, for Cell Banks, 2018 - 2030 (USD Million)
• Fig. 40 Global Mycoplasma Testing Market, for Contract Research Organizations, 2018 - 2030 (USD Million)
• Fig. 41 Global Mycoplasma Testing Market, for Academic & Research Institutes,
• Fig. 42 Global Mycoplasma Testing Market, for Others, 2018 - 2030 (USD Million)
• Fig. 43 Regional Marketplace: Key Takeaways Mycoplasma Testing Market, Region 2018 - 2030 (USD Million)
• Fig. 44 Mycoplasma Testing Market :Regional Outlook, 2023 & 2030, 2018 - 2030 (USD Million)
• Fig. 45 North America Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 46 U.S. Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 47 Canada Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 48 Europe Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 49 Germany Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 50 UK Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 51 France Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 52 Italy Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 53 Spain Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 54 Denmark Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 55 Sweden Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 56 Norway Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 57 Russia Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 58 Asia Pacific Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 59 Japan Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 60 China Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 61 India Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 62 Australia Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 63 South Korea Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 64 Thailand Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 65 Singapore Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 66 Latin America Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 67 Brazil Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 68 Mexico Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 69 Argentina Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 70 Middle East and Africa Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 71 South Africa Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 72 Saudi Arabia Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 73 UAE Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• Fig. 74 Kuwait Mycoplasma Testing Market, 2018 - 2030 (USD Million)

Mycoplasma Testing Market Growth & Trends:

The global mycoplasma testing market size is expected to reach USD 2.26 billion by 2030, registering a CAGR of 13.58% over the forecast period, according to a new report by Grand View Research, Inc. The major factors driving the expansion of market includes growing demand for mycoplasma testing in biomanufacturing, emerging economies, and growing pharmaceutical outsourcing. Additionally, the market's overall growth is driven by rising cell-line contamination and innovation & research in biological sciences.

Growing number of government initiatives to support pharmaceutical and biotechnology companies is also driving the market growth. The U.S. FDA proposed to remove a test for detecting mycoplasma within in vitro living cell cultures, as it can help identify only a single test method. These changes in biologics regulations are anticipated to improve specificity and sensitivity in mycoplasma detection tests, leading to introduction of new technologies in the industry. This is expected to create immense opportunities for key players in new product development.

The rates of M. pneumoniae positivity sharply decreased during the COVID-19 pandemic outbreak at the end of 2019. This was a result of the COVID-19 pandemic's stringent regulations, which successfully stopped the spread of M. pneumonia. However, it is anticipated that M. pneumonia will expand even more throughout the research period following the relaxation of COVID-19 limits, which will have a positive impact on the mycoplasma testing market's growth.

Increasing investments in R&D have contributed significantly to the market's revenue growth. With rising healthcare expenditure, research activities in the life sciences industry are increasing significantly. The adoption of new technologies for drug discovery & development and innovations in cell culture technologies are driving the demand for mycoplasma tests. The high risk of cell culture contamination remains the primary factor expected to drive the mycoplasma testing market over the forecast period

Mycoplasma is estimated to contaminate around 15%-35% of all continuous cell cultures around the world. Out of over 190 known species of mycoplasma, only eight species are responsible for more than 95% of cell culture contamination. Poor cultural practices, aerosols, dust, and cross-contamination as a result of faulty or broken laminar flow are some of the factors responsible for an increase in the number of cell culture contamination events. Such factors are likely to drive the market demand for mycoplasma testing solutions.

Mycoplasma Testing Market Report Highlights:

• By product, kits and reagents dominated the market, and are anticipated to exhibit the fastest CAGR throughout the forecast period, due to their widespread use in mycoplasma testing
• Ease of conducting the procedure and rapid detection are some of the major advantages offered by the PCR method
• By application, the cell line testing segment held a largest share of 41.65% in 2023, owing to the increase in research projects being done in the field of cell culture
• Mycoplasma contamination can cause alterations in cell culture metabolites and lead to development of toxins. This increases the importance of cell line testing and authentication in the pharmaceutical and biopharmaceutical industries
• North America held the largest share of 39.04% in 2023. This is mostly attributed to the presence of significant market participants, as well as rising R&D spending and federal assistance
• In Asia Pacific, the market is expected to grow at the highest rate in a projected time period driven by factors such as the rising prevalence of target diseases with an aging population, rising awareness and others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Test Segment
    • 1.1.1.2 Service Provider Segment
    • 1.1.1.3 Application Segment
• 1.2 Regional Scope
• 1.3 Estimates and Forecasts Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List of Secondary Sources
• 1.11 List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Increasing R&D investments in life sciences
  • 3.4.2. Rising government support toward pharmaceutical and biotechnology industries
  • 3.4.3. Rising cell culture contamination
  • 3.4.4. Growing demand for the introduction of effective treatment of life-threatening diseases
  • 3.4.5. Increased competition in the market
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost of research in cell biology
  • 3.5.2. Slow rate of mycoplasma growth
  • 3.5.3. Possibility of false negative results
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis
• 3.7. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Mycoplasma Testing Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
• 4.3. Kits & Reagents
  • 4.3.1. Kits & Reagents Market, 2018 - 2030 (USD Million)
  • 4.3.2. PCR Assays
    • 4.3.2.1. PCR Assays Market, 2018 - 2030 (USD Million)
  • 4.3.3. Nucleic Acid Detection Kits
    • 4.3.3.1. Nucleic Acid Detection Kits Market, 2018 - 2030 (USD Million)
  • 4.3.4. Stains
    • 4.3.4.1. Stains Market, 2018 - 2030 (USD Million)
  • 4.3.5. Elimination Kits
    • 4.3.5.1. Elimination Kits Market, 2018 - 2030 (USD Million)
  • 4.3.6. Standards & Controls
    • 4.3.6.1. Standards & Controls Market, 2018 - 2030 (USD Million)
  • 4.3.7. Others
    • 4.3.7.1. Others Market, 2018 - 2030 (USD Million)
• 4.4. Services
  • 4.4.1. Services Market, 2018 - 2030 (USD Million

Chapter 5. Technology Business Analysis

• 5.1. Mycoplasma Testing Market: Technology Movement Analysis
• 5.2. PCR
  • 5.2.1. PCR Market, 2018 - 2030 (USD Million)
• 5.3. ELISA
  • 5.3.1. ELISA Market, 2018 - 2030 (USD Million)
• 5.4. Direct Assay
  • 5.4.1. Direct Assay Market, 2018 - 2030 (USD Million)
• 5.5. Indirect Assay
  • 5.5.1. Indirect Assay Market, 2018 - 2030 (USD Million)
• 5.6. Microbial Culture Techniques
  • 5.6.1. Microbial Culture Techniques Market, 2018 - 2030 (USD Million)
• 5.7. Enzymatic Methods
  • 5.7.1. Enzymatic Methods Market, 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Mycoplasma Testing Market: Application Movement Analysis
• 6.2. Cell Line Testing
  • 6.2.1. Cell Line Testing Market, 2018 - 2030 (USD Million)
• 6.3. Virus Testing
  • 6.3.1. Virus Testing Market, 2018 - 2030 (USD Million)
• 6.4. End of Production Cells Testing
  • 6.4.1. End of Production Cells Testing Market, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. End-use Business Analysis

• 7.1. Mycoplasma Testing Market: End-use Movement Analysis
• 7.2. Pharmaceutical & Biotechnology Companies
  • 7.2.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
• 7.3. Cell Banks
  • 7.3.1. Cell Banks Market, 2018 - 2030 (USD Million)
• 7.4. Contract Research Organizations
  • 7.4.1. Contract Research Organizations Market, 2018 - 2030 (USD Million)
• 7.5. Academic & Research Institutes
  • 7.5.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Mycoplasma Testing Market Share By Region, 2023 & 2030
• 8.2. North America
  • 8.2.1. SWOT Analysis
  • 8.2.2. North America Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.2.3. U.S.
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Reimbursement Scenario
    • 8.2.3.6. U.S. Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.2.4. Canada
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Target Disease Prevalence
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Regulatory Framework
    • 8.2.4.5. Reimbursement Scenario
    • 8.2.4.6. Canada Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. SWOT Analysis
  • 8.3.2. Europe Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Reimbursement Scenario
    • 8.3.3.6. Germany Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.4. UK
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Reimbursement Scenario
    • 8.3.4.6. UK Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.5. France
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Reimbursement Scenario
    • 8.3.5.6. France Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.6. Italy
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Reimbursement Scenario
    • 8.3.6.6. Italy Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.7. Spain
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Reimbursement Scenario
    • 8.3.7.6. Spain Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.8. Denmark
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Reimbursement Scenario
    • 8.3.8.6. Denmark Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.9. Sweden
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Reimbursement Scenario
    • 8.3.9.6. Sweden Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.10. Norway
    • 8.3.10.1. Key Country Dynamics
    • 8.3.10.2. Target Disease Prevalence
    • 8.3.10.3. Competitive Scenario
    • 8.3.10.4. Regulatory Framework
    • 8.3.10.5. Reimbursement Scenario
    • 8.3.10.6. Norway Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.11. Russia
    • 8.3.11.1. Key Country Dynamics
    • 8.3.11.2. Target Disease Prevalence
    • 8.3.11.3. Competitive Scenario
    • 8.3.11.4. Regulatory Framework
    • 8.3.11.5. Reimbursement Scenario
    • 8.3.11.6. Russia Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. SWOT Analysis
  • 8.4.2. Asia Pacific Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.3. Japan
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Reimbursement Scenario
    • 8.4.3.6. Japan Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.4. China
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. Reimbursement Scenario
    • 8.4.4.6. China Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.5. India
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Reimbursement Scenario
    • 8.4.5.6. India Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.6. South Korea
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Reimbursement Scenario
    • 8.4.6.6. South Korea Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.7. Australia
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Reimbursement Scenario
    • 8.4.7.6. Australia Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.8. Thailand
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Reimbursement Scenario
    • 8.4.8.6. Thailand Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.9. Singapore
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Target Disease Prevalence
    • 8.4.9.3. Competitive Scenario
    • 8.4.9.4. Regulatory Framework
    • 8.4.9.5. Reimbursement Scenario
    • 8.4.9.6. Singapore Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. SWOT Analysis
  • 8.5.2. Latin America Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.5.3. Brazil
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Reimbursement Scenario
    • 8.5.3.6. Brazil Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Reimbursement Scenario
    • 8.5.4.6. Mexico Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.5.5. Argentina
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Competitive Scenario
    • 8.5.5.4. Regulatory Framework
    • 8.5.5.5. Reimbursement Scenario
    • 8.5.5.6. Argentina Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• 8.6. MEA
  • 8.6.1. SWOT Analysis
  • 8.6.2. MEA Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.6.3. South Africa
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Reimbursement Scenario
    • 8.6.3.6. South Africa Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.6.4. Saudi Arabia
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. Reimbursement Scenario
    • 8.6.4.6. Saudi Arabia Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.6.5. UAE
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Reimbursement Scenario
    • 8.6.5.6. UAE Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.6.6. Kuwait
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Competitive Scenario
    • 8.6.6.4. Regulatory Framework
    • 8.6.6.5. Reimbursement Scenario
    • 8.6.6.6. Kuwait Mycoplasma Testing Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1 Company Categorization
• 9.2 Strategy Mapping
  • 9.2.1 New Product Launch
  • 9.2.2 Partnerships
  • 9.2.3 Acquision
  • 9.2.4 Collaboration
  • 9.2.5 Funding
• 9.3 Key Company Market Share Analysis, 2023
• 9.4 Company Profiles
  • 9.4.1 Thermo Fisher Scientific, Inc.
    • 9.4.1.1 Company overview
    • 9.4.1.2 Financial performance
    • 9.4.1.3 Product benchmarking
    • 9.4.1.4 Strategic Initiatives
  • 9.4.2 Merck & Co., Inc.
    • 9.4.2.1 Company overview
    • 9.4.2.2 Financial performance
    • 9.4.2.3 Product benchmarking
    • 9.4.2.4 Strategic Initiatives
  • 9.4.3 Lonza Group AG
    • 9.4.3.1 Company overview
    • 9.4.3.2 Financial performance
    • 9.4.3.3 Product benchmarking
    • 9.4.3.4 Strategic Initiatives
  • 9.4.4 Charles River Laboratories International, Inc.
    • 9.4.4.1 Company overview
    • 9.4.4.2 Product benchmarking
    • 9.4.4.3 Strategic Initiatives
  • 9.4.5 PromoCell GmbH
    • 9.4.5.1 Company overview
    • 9.4.5.2 Financial performance
    • 9.4.5.3 Product benchmarking
    • 9.4.5.4 Strategic Initiatives
  • 9.4.6 Asahi Kasei Medical Co., Ltd.
    • 9.4.6.1 Company overview
    • 9.4.6.2 Financial performance
    • 9.4.6.3 Product benchmarking
    • 9.4.6.4 Strategic Initiatives
  • 9.4.7 Sartorius AG
    • 9.4.7.1 Company overview
    • 9.4.7.2 Financial performance
    • 9.4.7.3 Product benchmarking
    • 9.4.7.4 Strategic Initiatives
  • 9.4.8 InvivoGen
    • 9.4.8.1 Company overview
    • 9.4.8.2 Financial performance
    • 9.4.8.3 Product benchmarking
    • 9.4.8.4 Strategic Initiatives
  • 9.4.9 Eurofins Scientific
    • 9.4.9.1 Company overview
    • 9.4.9.2 Financial performance
    • 9.4.9.3 Product benchmarking
    • 9.4.9.4 Strategic Initiatives
  • 9.4.10 (ATCC) American Type Culture Collection
    • 9.4.10.1 Company overview
    • 9.4.10.2 Financial performance
    • 9.4.10.3 Product benchmarking
    • 9.4.10.4 Strategic Initiatives